Hydromorphone
Hydromorphone
复制标题
DOI：
10.1016/j.jpainsymman.2005.01.007
复制
发表时间：
2005-05-01
影响因子：
4.7
通讯作者：
Hagen, NA
中科院分区：
文献类型：
--
作者：
Murray, A;Hagen, NA
氢吗啡酮是一种半合成阿片类药物，已广泛用于急性疼痛，慢性癌症疼痛，并在较小程度上用于慢性非恶性疼痛。其药代动力学和药效学已得到充分研究，包括速释口服制剂、各种缓释口服制剂，以及通过静脉、皮下、硬膜外、鞘内等途径给药。已知其被代谢为与神经兴奋状态和其他毒性相关的镇痛非活性代谢物。没有证据表明氢吗啡酮比其他阿片类药物有更大的滥用倾向。需要进一步的研究来解决剩余的不确定性领域：等镇痛比;与其他阿片类药物相比的相对毒性风险，其在非恶性疼痛中的使用，以及特定氢吗啡酮代谢物在毒性发展中的作用，特别是与器官衰竭相关。(c)2005年美国癌症疼痛缓解委员会。爱思唯尔公司出版All rights reserved.
Hydromorphone is a semi-synthetic opioid that has been used widely for acute pain, chronic cancer pain and to a lesser extent, in chronic nonmalignant pain. Its pharmacokinetics and pharmacodynamics have been well studied, including immediate release oral preparations, a variety of slow release oral preparations, as well as administration through intravenous, subcutaneous, epidural, intrathecal and other routes. It is known to be metabolized to analgesically inactive metabolites that have been associated with neuroexcitatory states and other toxicity. There is no evidence that hydromorphone has any greater abuse liability than other opioids. Further research is needed to address remaining areas of uncertainty: equianalgesic ratios; relative risk of toxicity compared with other opioids, its use in nonmalignant pain, and the role of specific hydromorophone metabolites in the development of toxicity, particularly in association with organ failure. (c) 2005 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.